I have always been a curious person. Tell me, show me, and let me learn the facts about everything I am involved in.

I woke up very early this morning with my curiosity in high gear. Why are my Lecanemab infusion side effects delayed a day or two after the infusion? With a cup of coffee in hand (thank you to the unknown person who sent the Cuisinart Grind & Brew Single-Serve Coffee Maker – I LOVE IT), I started digging deep into the internet.

The first thing I learned is that the 60-minute infusion only puts the Lecanemab into my bloodstream. None of the Lecanemab crosses the blood-brain barrier (BBB) during the actual infusion process. Crossing the BBB is a much slower, passive biological process that takes place over days and weeks after the infusion is complete. Based on several articles I read, this is a common misconception.

During the two weeks between infusions, about 0.1% of the Lecanemab in my blood crosses the BBB. This is inefficient! Researchers are working on new technologies to penetrate the BBB. Focused ultrasound seems promising.

While sipping coffee and petting Big Bit, I found an article that discussed the FDA’s Adverse Event Reporting System (FAERS). From that article, I jumped to the actual reporting system. For anyone who loves data, FAERS is your jam! This is a database that allows drilling down to the most detailed information you can imagine.

I went to Lecanemab and began digging. There are a lot of adverse events listed - even deaths. I think it is important to balance the adverse events with the benefits. I knew Lecanemab came with risks when I decided to take it. The adverse events are greater than I expected though.

My awesome primary infusion physician at Duke Neurology prescribes medications that successfully manage my adverse events. I am confident Duke takes every precaution possible to keep every patient taking Lecanemab as safe as possible.

Do all hospitals and infusion centers take those same precautions? I certainly hope so.

My only disappointment with Duke and Eisai Inc. (the lead company for Lecanemab’s development and the final decision maker) is the lack of full transparency during the treatment decision-making process. Linda and I met with several Duke Neurology staff, and they explained the two treatment options - Lecanemab and Donanemab. We were provided literature for both drugs. The risks were clearly explained. Yet, looking back, full transparency about adverse events was missing.

Let’s set the stage for that meeting. Linda and I were scared beyond words. We knew our world was being turned upside down due to my Alzheimer’s diagnosis. More importantly, we did not fully understand Alzheimer’s disease. We were unaware of current treatment research. At that moment at Duke, Lecanemab seemed to be my best treatment option.

After seventeen infusions, the scenario is much different than the day we agreed to take Lecanemab. I have become an amateur expert on Alzheimer’s disease, emerging treatments, research challenges, Lecanemab, and the horrible realities of the disease. I have experienced the adverse effects of Lecanemab - ranging from intense shaking during chills to painful body aches.

Today, I am an educated Alzheimer’s patient.

I would make the same decision today that we made at Duke in September 2025. I would choose Lecanemab as my best treatment option. My frustration is that more transparent information was not provided by both Duke and Eisai. Looking back, I believe enough information was provided about the risks of Lecanemab to meet regulatory and liability requirements, while positioning the drug as a great treatment for my Alzheimer’s.

As a life-long business owner, I understand the need to sell and keep revenue flowing. For pharmaceutical companies, revenue funds research. I also believe an educated consumer is a better long-term supporter of a product and manufacturer. In the case of Duke and Eisai, transparency about adverse effects would not have changed the decision I made. It would have made me prepared, set true expectations, and made me a happier patient.

In recent months, I have shared these thoughts with Eisai.

I believe a video with a patient talking about their Lecanemab experience is needed. Show the infusion process, explain the possible adverse events, suggest preparations for adverse events, show an MRI, and talk about the great potential benefits of Lecanemab. Create an informed patient, not a frightened one.

Time for more coffee. Have a great Sunday.

Greg

Greg’s Alzheimer’s Research Report

Donations

$5 Sponsorship Donation

$10 Sponsorship Donation

$25 Sponsorship Donation

Go Fund Me (amounts greater than $25)

Buy Big Bit A Treat (small donations)

Amazon Wish List (things that Linda and Greg need)

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

This has been a busy and somewhat frustrating week for Linda and me.

Linda continues to have physical therapy in our apartment. It seems to be going according to plan. She is using a wheelchair less and a walker more.

My infusion went well Tuesday. I had no side effects Tuesday afternoon. About 1:00 am Wednesday, I became nauseated. About 5:00 am, I had severe pain (muscle aches) in my forearms. This pain continued throughout the day. I had to reschedule a doctor appointment.

I felt much better Thursday. Linda and I acted like cats all day. Long naps with breaks for a snack.

Early this morning, I woke with muscle aches in my right leg. I find it interesting that my Lecanemab infusion side effects are generally delayed several days after the infusion.

At 10:00 am today, I had a biopsy at Duke Neurology as the first step in the Syn-One Test. This is a comprehensive lab test that detects abnormal proteins in cutaneous nerves to diagnose neurodegenerative disorders. There are indications that I may have some form of Parkinsonism. The Syn-One test will provide the answers.

After the biopsy, I went upstairs in the neurology building to the home of the i-MIND Research Group. I am joining the i-MIND study as a participant. In simple terms, this study is trying to learn if retinal images can diagnose neurological diseases. I wrote about the i-MIND study in Greg’s Alzheimer’s Research Report yesterday.

To wrap up the week, we learned that the scheduled closing on our South Carolina home is delayed by a few days. Rather than June 2, the closing will probably be June 4. I am told the delay is a minor issue.

Subscribers to the blog continue to grow. Welcome to each and every new subscriber. Please leave a comment or ask a question. I want the blog to be a community where we share and learn together.

If you have not visited Greg’s AZ Store lately, there are many great summer shirts in stock. We have sizes and styles for all ages.

Have a wonderful weekend.

Greg

Greg’s Alzheimer’s Research Report

Donations

$5 Sponsorship Donation

$10 Sponsorship Donation

$25 Sponsorship Donation

Go Fund Me (amounts greater than $25)

Buy Big Bit A Treat (small donations)

Amazon Wish List (things that Linda and Greg need)

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

I woke up this morning with something on my mind. I am testing producing short form videos for a YouTube channel. The first video is related to the amyloid cascade hypothesis. This unproven hypothesis has been controversial since it was published in 1992. The amyloid cascade hypothesis is what I was thinking about when I woke up (actually, I had coffee before I started any serious thinking!)

I spent the morning researching and writing an editorial for Greg’s Alzheimer’s Research Report. The subject has broad interest, so I decided to cross post it to My Alzheimer’s Journey. You should receive a non-paywall version in a few minutes.

This is the first time I have written an editorial based on personal opinion.

I would love to hear your thoughts by leaving a comment.

Enjoy the long weekend if you are in the USA. Otherwise, have a great rest of your weekend.

Greg

The reason for the lack of a road map, is that everyone’s Alzheimer’s journey is unique.

The disease progresses differently for everyone. Support systems vary widely. Treatment options are patient specific. The financial impact is significant for all patients; yet, there is no blueprint or standard plan. Indirect illnesses range from depression to urinary tract infections, with no advance warning.

As I continue down the rocky road of Alzheimer’s, I have encountered a number of obstacles, potholes, and unexpected hazards. My journey also includes surprise encounters of generosity, compassionate care, and support from strangers. The most shocking aspect of my journey is the often erratic and irresponsible actions of the United States government. I keep thinking about the seven million Americans who suffer with Alzheimer’s. I bet the cost of the proposed Trump Arch would fund the research needed to find a cure for Alzheimer’s.

My greatest struggle is avoiding depression. There are days when I am physically exhausted, the body chills are endless, and I can’t remember the day of the week. That is when I question my purpose. I ask myself why the long goodbye has to be so damn long. Those are the dark days.

I miss going to work, being creative, building things, getting paid, and seeing the smiles of happy clients. Those activities are not allowed on my Alzheimer’s journey. Poor memory, inability to make sound decisions, frequent confusion, twitching hands, and lack of energy are not considered great skills in the construction industry.

I am learning how to repackage, reformat, and repurpose many of the skills I have.

To keep my entrepreneurial spirit alive, I have started a few small ventures with Linda as my partner, and Big Bit as my emotional support cat. My new purpose is Alzheimer’s advocacy. I hope my talents, skills, and experiences can be put to use to make a difference for those who come behind me on the Alzheimer’s journey.

To help me navigate the road ahead and beat back the depression that is always lurking in the shadows, I try to stay focused on the positive aspects of my life.

Speaking of positive, some wonderful things have happened since my last blog update:

• Linda and I received a generous gift from an anonymous giver. I enjoy making my coffee with the state-of-the-art grinder/brewer. The Instant Pot will be used for the first time this weekend. If I can train the cats to make my coffee (and serve it to me in bed), I will be overwhelmingly happy.

• I learned that I do not need cataract surgery. It always pays to get a second opinion.

• Linda’s leg fracture is slowly healing. After a visit to the doctor yesterday, It seems that surgery is not needed. She still has a long road to full recovery, though.

• Baring any last minute hiccups, our South Carolina home will be sold the first week of June. We are selling for much less than we hoped; but, we are happy to hand the keys to someone else.

Your support helps me navigate the numerous road hazards I encounter daily.

I am so grateful to have you alongside me on my Alzheimer’s journey.

Greg’s Alzheimer’s Research Report

Donations

$5 Sponsorship Donation

$10 Sponsorship Donation

$25 Sponsorship Donation

Go Fund Me (amounts greater than $25)

Buy Big Bit A Treat (small donations)

Amazon Wish List (things that Linda and Greg need)

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

Happening down the street at Greg’s Alzheimer’s Research Report is a story about a small pharmaceutical company that is developing a promising adjunct drug to help manage cognitive impairments associated with mild-to-moderate Alzheimer’s disease.

The drug is known as Masitinib. They plan to start the Phase 3 clinical trial this year. All trial locations are in Europe (Spain and France). If you live in the United States, participating in a clinical trial in Europe seems like an awesome adventure.

Head over and learn more about AB Science and Masitinib. Don’t forget to hit the subscribe button!

I'm looking forward to updating you on my journey Friday.

I have just published Genes Linked To Alzheimer’s Disease in the new publication, Greg’s Alzheimer’s Research Report.

I have an important announcement regarding the future structure of My Alzheimer’s Journey. To better serve this community and ensure the sustainability of my work, I am splitting the blog into two separate, focused publications.

1. My Alzheimer’s Journey (Current Blog)

• Focus: My personal journey as an Alzheimer’s patient, delivered with authenticity and humor.

• Frequency: Once per week. Most likely Friday.

• Cost: Free, voluntary donations are appreciated.

2. Greg’s Alzheimer’s Research Report

• Focus: Comprehensive, technical, and commercial intelligence on Alzheimer’s disease.

• Content Includes: New treatments, clinical trials, emerging research, scientific conferences, and biotech/pharmaceutical updates.

• Frequency: Five times per week (Monday – Friday).

• Cost: Subscription required ($10/month or $100/year).

My goal is to give each publication the attention it deserves. While Alzheimer’s research and my journey as someone with Alzheimer’s disease are intertwined, the writing style, or narrative, is different. With separate publications, I can share my journey in a casual and authentic style. The research publication will have a more structured format.

You will continue to receive my weekly personal posts here, free of charge. For those who want daily, in-depth scientific reporting, the new publication is designed specifically for you.

Greg’s Alzheimer’s Research Report is not a newsletter you have to find time to read - it’s the one that saves you time. I cut through the noise of the scientific community to bring you the latest updates on Alzheimer’s research.

• Deep Research, Plain English: I summarize the most complex, technical, and scientific information on Alzheimer’s disease and new treatments, delivering it in clear, understandable language.

• Daily, Focused Updates: Receive a new publication Monday through Friday, ensuring you are current in the fast-moving world of Alzheimer’s research and clinical trials.

• Save Hours of Searching: Stop wading through on-line scientific journals and press releases. My carefully researched articles consolidate information on:

• New Treatment Research and Updates

• In-Depth Clinical Trial Information (including Phase 3 trials like Masupirdine and registrational development like Diranersen)

• Biotech and Pharmaceutical Company Movements

• Coverage of Scientific Conferences (like AAIC)

• Fast & Convenient: Each issue is designed to be a fast, 10-minute read, integrating seamlessly into your busy schedule.

• Trusted Independent Voice: As a patient with Alzheimer’s, my personal interest guarantees the research is relevant and crucial to our community.

The Value Proposition: Essential Intelligence for Less Than a Cup of Coffee

· Access to this level of consistency, expertly curated, and patient-focused analysis is invaluable. The subscription is priced at just $10 per month, or you can receive a significant discount by choosing the annual plan for $100 per year.

· For less than 42 cents per publication (or as low as 38 cents with the annual plan), you get daily access to the critical information you need—freeing you from spending hours researching and ensuring you are always informed about the latest options and breakthroughs.

Greg’s Alzheimer’s Research Report is live with a new article published today. There is a free seven-day trial available.

Thank you for your support. I look forward to our continued friendship.

With gratitude,

Greg

Donations

$5 Sponsorship Donation

$10 Sponsorship Donation

$25 Sponsorship Donation

Go Fund Me (amounts greater than $25)

Buy Big Bit A Treat (small donations)

Amazon Wish List (things that Linda and Greg need)

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

On February 10, I wrote about Biogen’s Diranersen (BIIB080), an investigational drug designed to reduce the production of tau protein. Diranersen was developed by Ionis Pharmaceuticals. In late 2019, Biogen exercised a license option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize Diranersen. In April 2025, the FDA granted Fast Track designation to the Diranersen Phase 2 CELIA clinical trial.

Over the past month or two, I have heard rumblings that the Phase 2 CELIA clinical trial was not going well. Yesterday, Biogen announced that it will move ahead with registrational development of Diranersen. Registrational development is also known as a pivotal trial. These trials are generally Phase 3 studies.

What is interesting (and confusing) is that according to the Biogen press release, “the Phase 2 CELIA clinical trial had compelling topline results.” Priya Singhal, M.D., M.P.H., Executive Vice President and Head of Development at Biogen said, “We are excited by these Phase 2 data, which give us the confidence to advance Diranersen to registrational development. We look forward to engaging with regulators and the broader Alzheimer’s disease community on next steps. I would like to thank the patients, families, investigators, and study teams who participated in this pioneering study.” As I scrolled down through the rather lengthy press release, I found this statement: “CELIA did not meet its primary endpoint assessing dose response for change from baseline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 76.”

This is why I am confused. Why is Biogen pushing forward with the registrational development of Diaranersen? Maybe they have seen enough, and they are super confident, and they simply decided to get the Phase 3 trial going.

In plain English, the Phase 2 CELIA trial failed to meet its primary endpoint of showing a dose-response relationship in patients with early Alzheimer’s disease. The study did not demonstrate that higher doses were more effective than lower doses in reducing clinical decline.

These are the key results of the Phase 2 CELIA trial:

• Failed Endpoint: The study missed the main goal of demonstrating that higher doses (115 mg) worked better than the lowest dose (60 mg).

• Best Efficacy at Lowest Dose: Unexpectedly, the strongest evidence of slowed cognitive decline was seen at the lowest dose tested (60 mg every 24 weeks).

• Target Reduction Achieved: Despite missing the primary endpoint, Diranersen showed “robust reductions” in tau protein in the cerebrospinal fluid (CSF) and brain pathology (tau PET) across all doses tested, supporting its mechanism as a tau-targeting antisense oligonucleotide.

• Safety Profile: The safety profile was generally consistent with previous studies, though a higher incidence of serious adverse events was observed at the highest dose

Biogen promises to present the full Phase 2 CELIA data at the Alzheimer’s Association International Conference (AAIC) 2026. This conference is being held in London July 12 - 15.

In my opinion, there is a bit of spin going on at Biogen. Frankly, I understand why. There is a lot riding on the success of Diaranersen. Biogen’s shares sank in value by about 5% yesterday after the Diaranersen announcement.

As I stated when I first wrote about Diaranersen, I believe the drug has great potential. Diranersen is designed to reduce both extracellular and intracellular tau. Most other research efforts have focused only on extracellular tau. Pre-clinical studies were positive. Clearly, the Biogen team is confident that Diaranersen can achieve its objectives. This registrational development trial is extremely important.

Specific details on the registrational development trial have not been released.

In other Biogen news, they completed the purchase of Apellis Pharmaceuticals today. Apellis is a Massachusetts-based biotech company focused primarily on rare disease therapies. With the acquisitions, Biogen gains two commercial drugs, Empaveli and Syfovre.

Apellis was delisted from the NASDAQ exchange yesterday and the company is now a wholly owned subsidiary of Biogen. Each Apellis shareholder received $41 per share in cash. Based on future Syfovre sales, Apellis shareholders may receive additional cash somewhere down the road. Biogen borrowed roughly two billion dollars to close the deal.

Sources:

Biogen Press Release - May 14, 2026

Seeking Alpha - May 15, 2026

First Word Pharma - May 14, 2026

Medical Dialogues - May 15, 2026

Keeping this blog sustainable requires a community effort. If you are in a position to help, please consider a donation today.

Donations

$5 Sponsorship Donation

$10 Sponsorship Donation

$25 Sponsorship Donation

Go Fund Me (amounts greater than $25)

Buy Big Bit A Treat (small donations)

Amazon Wish List (things that Linda and Greg need)

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

Terminal lucidity is an unexpected period of mental clarity and memory shortly before death in patients suffering from Alzheimer’s and other neurologic disorders. It is often referred to as an end of life rally. For caregivers and family, this phenomenon can be confusing and a bit unsettling. Some people have mistaken terminal lucidity as hope that the loved one is getting better.

Christopher Kerr, chief executive officer and chief medical officer at Hospice and Palliative Care Buffalo in New York State, has studied the lucid visions of several hundred terminally ill people. He says these events “usually occur in the last few days of life.”

It is estimated 43 percent of people who experience this brief lucidity die within 24 hours, and 84 percent within a week.

The signs of terminal lucidity include:

• Remembering and reacting to loved ones after being disengaged for an extended period of time

• Speaking coherently

• Expressing their desires such as requesting a favorite food

• Recognizing people they had forgotten

• Recount experiences in great detail

• Singing or playing a musical instrument

Despite being reported since the 19th century, the cause of terminal lucidity is not well understood and is a subject of ongoing research. Some researchers suggest that it may be related to the dying brain losing its usual suppression mechanisms, allowing access to previously inaccessible parts of the brain. Other theories propose that it could be a result of the brain attempting to restore cognitive abilities in individuals who are otherwise considered permanently impaired.

One thing is certain, terminal lucidity is perplexing and mysterious, and maybe even mystical.

If your loved one experiences terminal lucidity, the Cleveland Clinic suggests you be present for them. Allow them to steer the conversation. Keep the conversation simple. Finally, make the lucid moment matter. Say comforting words before your loved one dies.

Have you witnessed terminal lucidity? If so, please share your experience by leaving a comment.

Sources:

Terminal lucidity: A review and a case collection - Archives of Gerontology and Geriatrics, Volume 55, Issue 1

Why Dying People Often Experience a Burst of Lucidity - Scientific American, June 12, 2023

Please remember that the writer (me) needs to be fed.

If you are in a position to help, please donate today. Even $5 makes a difference.

Thank you for walking this path with me. Your presence here means more than I can say, and your support keeps this light on for everyone.

With gratitude,

Greg

Donations

$5 Sponsorship Donation

$10 Sponsorship Donation

$25 Sponsorship Donation

Go Fund Me (amounts greater than $25)

Buy Big Bit A Treat (small donations)

Amazon Wish List (things that Linda and Greg need)

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

I received my 16th infusion of Lecanemab this morning. If you suffer from Alzheimer’s disease, Lecanemab is waaaay better than cake and ice cream. I might have to enjoy some Thrive ice cream later tonight, though.

Big shout out to Orange County, North Carolina Department of Aging. They have a Volunteer Driver Program that I used for the first time today. My driver was terrific, and the cost was amazing (ZERO). Thanks B and E (and L!).

Coming up tomorrow - I dig deep into terminal lucidity.

Please remember that the writer (me) needs to be fed.

If you are in a position to help, please donate today.

Thank you for walking this path with me. Your presence here means more than I can say, and your support keeps this light on for everyone.

With gratitude,

Greg

Donations

$5 Sponsorship Donation

$10 Sponsorship Donation

$25 Sponsorship Donation

Go Fund Me (amounts greater than $25)

Buy Big Bit A Treat (small donations)

Amazon Wish List (things that Linda and Greg need)

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

I have a mixed bag of news to share with you.

Eggs Reduce the Risk of Alzheimer’s

Let’s start with a just released study about eggs and Alzheimer’s disease (AD). May 4, 2026, Loma Linda University Health published an article stating that consumption of eggs is associated with a lower risk of AD. The article summarizes the Adventist Health Study-2 which was conducted by researchers at Loma Linda. The results of the study were published April 17, 2026, in the Journal of Nutrition.

The study included a population of 40,000 United States Seventh-day Adventists. Eligibility was determined using the Medicare Master Beneficiary Summary Files. The average follow-up period was 15.3 years. The study concluded that moderate egg consumption should be part of a balanced diet. Furthermore, moderate consumption of eggs leads to a lower risk of AD.

I am a tad puzzled why this study was conducted since there have been many previous studies that have concluded that moderate egg consumption reduces the risk of AD. For example, the Rancho Bernardo Study in 2024 concluded that, “eggs provide nutrients beneficial for cognitive function.” Also in 2024, the Rush Memory and Aging Project concluded that, “frequent egg consumption is associated with a lower risk of Alzheimer’s dementia and AD pathology”. In 2025, Henry Ford Health called eggs a “brain booster”.

Loma Linda University Health received some funding for their study from the American Egg Board. The Egg Board released a press announcement May 5, 2026, titled, “New and Consistent Data: Including Eggs as Part of a Balanced Diet is Associated with Reduced Risk of Alzheimer’s Disease.” This article is a summary of the Loma Linda study. Is it a conflict of interest smart marketing for the Egg Board to fund a research project that concludes that eating eggs reduces the risk of AD?

FDA Decision Delayed

Biogen and Eisai were expecting a decision from the FDA May 24, 2026, on the use of subcutaneous Lecanemab for treatment initiation. Last Friday, the FDA announced a three-month delay in their decision.

The FDA requested additional information regarding the use of subcutaneous Lecanemab for treatment initiation. The agency then said the information was a “major amendment to the application.” The FDA reviewers now have three additional months to review the data provided by Biogen and Eisai.

In September 2025, the FDA approved a subcutaneous formulation of Lecanemab. This approval, however, only applied to maintenance treatments. New patients would still have to undergo an 18-month period of bi-weekly intravenous infusions.

The new FDA application is to use this subcutaneous formulation to initiate patients, completely eliminating the need for intravenous infusions. If approved, this opens the possibility of at-home, subcutaneous dosing for the entirety of the treatment regimen.

The FDA decision is now expected August 24, 2026.

Important Legislation

Senate Bill 3267, called the “Alzheimer's Screening and Prevention Act” or the “ASAP Act” will provide for Medicare coverage of blood-based Alzheimer’s screening tests.

The House version of the Bill is H.R. 6130.

Please contact your Congressman and Senator and encourage them to vote for passage of this important legislation.

Keeping this light on (and accessible to all)

Writing My Alzheimer’s Journey is one of the most meaningful things I do, but it is also a labor of love that requires significant time, research, and resources.

When I started this blog, I made a conscious choice: I will never put this information behind a paywall. I know firsthand that caregivers are often under immense financial and emotional strain. I want every person—regardless of their bank account balance—to have access to the insights and support shared here.

However, keeping this journey sustainable requires a community effort.

Currently, only a small handful of our 350-strong community are able to donate. If you have found comfort, clarity, or a sense of “I’m not alone” in these words, I’m asking you to consider becoming a partner in this work.

Your donation doesn’t just pay for a website; it ensures that a daughter in over her head or a spouse feeling lost can find the resources they need at 2:00 AM, free of charge.

If you are in a position to help, please consider a donation today.

Thank you for walking this path with me. Your presence here means more than I can say, and your support keeps this light on for everyone.

With gratitude,

Greg

Donations

$5 Sponsorship Donation

$10 Sponsorship Donation

$25 Sponsorship Donation

Go Fund Me (amounts greater than $25)

Buy Big Bit A Treat (small donations)

Amazon Wish List (things that Linda and Greg need)

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

We started the week with the announcement that Axsome Therapeutics drug, Auvelity had received FDA approval for treatment of agitation due to Alzheimer’s disease. I read reports yesterday that several Wall Street analysts have updated the fair value estimate for Axsome Therapeutics stock (AXSM) from US$223.99 to US$266.94 since Auvelity’s approval. Analysts believe Auvelity will generate significant cash. Of course, that is assuming Auvelity will be successful treating agitation. My report Monday raised a few concerns about the efficacy of Auvelity. I will monitor Auvelity closely.

Tuesday, I wrote an update on my Alzheimer’s progression. I have good days and bad days. Overall, I am doing well. I credit Lecanemab for slowing the progression of my Alzheimer’s.

I did not post on Wednesday. On Thursday, I shared the fascinating story of Doug Whitney. Can you imagine expecting to develop Alzheimer’s disease in your 50’s since you carry a mutation of the Presenilin 2 gene; yet, you are now in your late 70’s without Alzheimer’s? If you missed my article, I encourage you to read it.

We wrapped the week up with an article about diets that may help prevent or slow down the progression of Alzheimer’s disease. With the information I learned about the MIND diet still fresh in my mind, Linda and I headed to our local Farmer’s Market this morning. It is a beautiful day and the sunshine felt wonderful. We bought some organic leafy greens and two locally made pastas. The pastas are mushroom ravioli and goat cheese and honey ravioli.

After consideration of numerous economic factors (the cost of gasoline, groceries, and damn near everything we consume), I am dropping the suggested minimum donation to support my writing. This doesn’t mean that donations are not needed. In fact, due the rising costs of everything we consume, I need your support more than ever.

Please donate at any level that feels right. You’ll receive full access to the blog, my new Saturday feature, The Week in Review, and a permanent 5% discount at my online store. Use the code, BLOG at checkout to receive your discount.

I never want a person’s financial situation to stand between them and the support they find here, but I also want to ensure My Alzheimer’s Journey is sustainable. If you’re able to, please consider contributing so I can continue to share insight with you and the many caregivers and families who are following My Alzheimer’s Journey.

I am so grateful to have you alongside me on my Alzheimer’s journey.

Donations

$5 Sponsorship Donation

$10 Sponsorship Donation

$25 Sponsorship Donation

Go Fund Me (amounts greater than $25)

Buy Big Bit A Treat (small donations)

Amazon Wish List (things that Linda and Greg need)

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

I plan to visit a farmer’s market tomorrow morning, so I have been researching the best diet for both the prevention of Alzheimer’s disease and the delay of AD progression. The Carrboro Farmer’s Market has an enviable reputation for locally grown organic food, craft baked items, and a strong sense of community. I am looking forward to my adventure.

According to a National Institute on Aging report, there are two diets that research has shown may hold cognitive benefits. The popular Mediterranean diet emphasizes fruits, vegetables, whole grains, legumes, seafood, and unsaturated fats such as olive oils. This diet recommends limited consumption of red meat, eggs, and sweets.

The other diet is called MIND (Mediterranean Intervention for Neurodegenerative Delay). It is a hybrid of the Mediterranean and the DASH (Dietary Approaches to Stop Hypertension) diet. This diet is similar to the Mediterranean diet, only it is more specific in certain areas. For example, it specifically recommends green leafy vegetables and berries over other fruit.

The MIND diet is easier to follow than the Mediterranean diet, which calls for daily consumption of fish and three to four daily servings of each of fruits and vegetables.

A 2023 clinical trial studied the MIND diet. The study was a two-site, randomized, controlled trial involving older adults without cognitive impairment but with a family history of dementia, The participants also had a “suboptimal diet”, as determined by a 14-item questionnaire, There were 604 participants - 301 assigned to the MIND diet and 303 assigned to the control-diet.

The trial was completed by 93.4% of the participants. The three-year study showed improvements in global cognition scores in both groups, with increases of 0.205 standardized units in the MIND-diet group and 0.170 standardized units in the control-diet group. Changes in white-matter hyperintensities ( "bright spots" found on MRI brain scans), hippocampal volumes, and total gray and white matter volumes on MRI were similar in the two groups. In summary, the outcomes did not differ significant differences between those who followed the MIND diet and those who followed the control diet with mild caloric restriction.

A Harvard University study of the MIND diet concluded, “the MIND diet can be a healthful eating plan.” The study goes on to say, “whether following the MIND diet can slow cognitive aging over longer time periods remains an area of interest, and more research needs to be done to extend the MIND studies in other populations.”

Rush University also studied the MIND diet. They were more positive and stated the MIND diet,“may reduce the incidence of brain disease that increases a person’s risk in developing Alzheimer’s disease.” Rush University may be a tad biases though. Martha Clare Morris, PhD, a Rush nutritional epidemiologist and her colleagues, developed the MIND diet.

Deciding to follow the MIND diet is a similar decision to using a sauna that I reported yesterday. There are numerous benefits to using a sauna and following the MIND diet even if the cognitive benefits are uncertain.

The MIND diet has 15 dietary components, including 10 brain-healthy food groups, and 5 unhealthy food groups.

The healthy food groups are:

• Green leafy vegetables

• Other vegetables

• Nuts

• Berries

• Beans

• Whole grains

• Fish

• Poultry

• Olive oil

• Wine

The five unhealthy groups are:

• Red meats

• Butter and stick margarine

• Cheese

• Pastries and sweets

• Fried or fast food

It looks like blueberries, leafy greens, vegetables, and organic chicken will be on my farmer’s market shopping list. I am going to Costco later today to pick up several prescriptions. I will get salmon while there.

Here are several MIND recipes and the official MIND diet website:

The Official MIND Diet

Eating Well

Mass General Hospital

Alzheimer's Tennessee

Have a great weekend. Thank you for your continued support.

$25 Purchase Now

Your support of my blog is greatly needed - and, appreciated.

There are three ways you can support the publication:

• Sometimes: Donate whatever you can, whenever you can. You will continue to have full access to the entire blog - nothing changes for you, and your support is deeply appreciated.

• Supporters (minimum donation of $25/month): You’ll receive full access to the blog, my new Saturday feature, The Week in Review, and a permanent 5% discount at my online store.

• Sponsors (minimum donation of $40/month): You’ll receive all the Supporter benefits plus a permanent 8% store discount and an invitation to a monthly live Zoom meeting. This will be an open space to talk, share, and ask me almost anything on your mind. I will schedule multiple times if needed to make sure our international friends can join in.

I never want a person’s financial situation to stand between them and the support they find here, but I also want to ensure My Alzheimer’s Journey is sustainable. If you’re able to, please consider contributing so I can continue to share insight with you and the many caregivers and families who are following My Alzheimer’s Journey.

Please support at the level that feels right for you. I am so grateful to have you alongside me on my Alzheimer’s journey.

Donations

Why I Ask for Donations

Sponsor Donations

Go Fund Me

Buy Big Bit A Treat

Amazon Wish List

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

Doug is in his late 70’s, and he does not have AD. His doctors and researchers at Washington University in St; Louis, believe Doug dodged the AD bullet due to his career as a mechanic on large ships. Doug worked for about twenty years in hot ship engine rooms for hours at a time. These engine rooms would reach temperatures of 50 degrees C (122 degrees F).

Possibly, as a result of his heat exposure, Doug has very high levels of heat shock proteins in his cerebrospinal fluid. These high levels of heat shock proteins may have prevented Doug from developing AD by regulating the tau in his brain. PET scans show Doug’s brain is full of amyloid plaque and very little tau protein. Amyloid plaque is a characteristic of AD; yet, it is tau that correlates to AD symptoms.

The New Scientist article goes into detail about testing that led researchers to believe that Doug’s exposure to heat is a factor in his lack of AD symptoms. Additionally, the article talks about lab tests where mice that were placed in miniature saunas had better tau protein structures. As I continued reading the article, I learned that geographic locations where there are very low incidences of AD also have some of the highest temperatures.

One example is Ballabhgarh, India where the average high temperature reaches around 40C to 41C (101F to 106F). This rural community in Northern India has the lowest recorded rates of AD in the world, with studies indicating a rate of just 0.62% in residents aged 55+ and 1.07% in those aged 65+. Researchers attribute this low rate of AD to a physically active lifestyle, a low-fat vegetarian diet, and low stress. Additionally, it is believed that the extreme heat has a role in preventing AD.

Being curious about the possible connection between high heat exposure and a low risk of developing AD, I started digging. A study published in 2020, found that “heat therapy can be of tremendous clinical benefit to patients with AD.”

In simple terms, this is the role of heat therapy in preventing AD:

1. Interorgan Cross Talk (Body Communication)

Heat therapy increases blood flow, which helps our body organs send “messages” back and forth more effectively. The messages are sent via endocytic vesicles (EV).

2. Heat Shock Proteins & Mitochondria

The EVs may contain Heat Shock Proteins (HSPs). These act like a repair crew. Their main job in this context is to fix the mitochondria (power plant of our cells) and restore proteostasis.

3. Proteostasis

Proteostasis is the cellular process that maintains a balanced and functional protein network. This process breaks down in AD. Heat therapy seems to trigger the process of proteostasis.

4. Metabolic Homeostasis

All the above effects can improve our whole body metabolic homeostasis (reducing blood glucose and insulin) and improve tissue-specific outcomes such as cognitive function.

In summary: heat therapy leads to better blood flow with messages sent via endocytic vesicles (EV). The EVs contain heat shock proteins (HSP). The HSP fixes the mitochondria (our cell power plants) and proteostasis. This results in clean cells and balanced metabolic homeostasis. Ultimately, our cognitive functions are improved.

Should we all go buy saunas or join a health club with saunas? Even if the sauna doesn’t prevent you from developing AD, you will enjoy these benefits:

• Improved cardiovascular function

• reduced blood pressure

• lower stress

• relief from chronic pain

• overall relaxation

• enhanced sleep quality

• detoxification through sweating

Or, become a ship engine mechanic, like Doug.

$25 Purchase Now

Your support of my blog is greatly needed - and, appreciated.

There are three ways you can support the publication:

• Sometimes: Donate whatever you can, whenever you can. You will continue to have full access to the entire blog - nothing changes for you, and your support is deeply appreciated.

• Supporters (minimum donation of $25/month): You’ll receive full access to the blog, my new Saturday feature, The Week in Review, and a permanent 5% discount at my online store.

• Sponsors (minimum donation of $40/month): You’ll receive all the Supporter benefits plus a permanent 8% store discount and an invitation to a monthly live Zoom meeting. This will be an open space to talk, share, and ask me almost anything on your mind. I will schedule multiple times if needed to make sure our international friends can join in.

I never want a person’s financial situation to stand between them and the support they find here, but I also want to ensure My Alzheimer’s Journey is sustainable. If you’re able to, please consider contributing so I can continue to share insight with you and the many caregivers and families who are following My Alzheimer’s Journey.

Please support at the level that feels right for you. I am so grateful to have you alongside me on my Alzheimer’s journey.

Donations

Why I Ask for Donations

Sponsor Donations

Go Fund Me

Buy Big Bit A Treat

Amazon Wish List

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

Every few weeks, I remind myself that the blog is titled, My Alzheimer’s Journey. It is easy for me to focus on emerging new treatments, clinical trials, caregiver tips, and Alzheimer’s disease history, and forget to write about my journey.

Next Tuesday, I will receive my 16th infusion of Lecanemab. In late March, I wrote about the infusion experience at the Duke Specialty Infusion Center. The process of receiving an infusion has become routine for me. There are familiar faces of other patients, smiles of caring nurses, the cheerful snack guy, and the warm blankets. I continue to be a strong supporter of Lecanemab. Based on recent data, I know Lecanemab slows the progression of Alzheimer’s disease. The question I have is, “what is next?”.

I am getting ahead of myself though.

While I have symptoms that are progressing, or worsening, I am still able to manage most daily activities. While Linda was at the rehab center for eleven nights, the cats and I survived with no major drama. There were a few cat skirmishes; but, we all ate well, the apartment stayed clean, and the litter boxes were scooped, I even cooked several meals (the cats and I love salmon!).

I have noticed an overall increase in confusion; especially, when I wake up in the morning. It is not uncommon for me to be unaware of where I am. The confusion is fleeting. Within a minute or so, I remember my surroundings and location.

My short-term memory continues to frustrate me. Making lists, using a calendar, and writing task reminders have become part of daily life. Conversations are challenging. It bothers me to not remember a name, a date, or an event while talking to someone. I am learning that the person I am talking to doesn’t care if I forget a detail. I pause, think for a few seconds, and boom the forgotten detail pops into my head.

One of my first Alzheimer’s symptoms doesn’t seem to be worsening; it is holding steady. I believe making poor decisions began several years ago. At the time, I just thought my age and exhaustion from working long hours resulted in some less than stellar decisions. These decisions were both large and small. They included hiring decisions, financial management, and even what I ate. One recurring poor decision I made was letting company trucks get very low on fuel (remind me to tell you later about a one ton diesel truck towing a large trailer with a backhoe running out of fuel on I-26 in the mountains of North Carolina.)

As I reflect on the poor decisions I made, I realize that I generally knew the decision I was making was not my best option. Yet, I went forward with the poor decision.

My writing has worsened in recent months. I often omit words from texts, emails, and long-form essays, blog posts, etc. I carefully proofread everything I write. Additionally, Linda reviews all the essays and blog posts. Fortunately, my ability to convey a thought, tell a story, or describe an event has not changed.

I have mild episodes of sundowning. Certain things trigger anxiety, agitation, and frustration. I do not experience sundowning if I avoid music or television that is even slightly loud, large crowds, and chaotic environments.

Stress triggers anxiety. The only stress in my life is financial. When our South Carolina home sells, I will be able to say goodbye to most of the financial stress. Making a mortgage payment and paying extremely high rent is a huge challenge.

Reduce My Stress By Donating $10

The big deal for me is depression. Most of my adult life I have suffered from Major Depressive Disorder. Until recently, medication managed my depression. Today, it takes a combination of medication, diet, and lifestyle choices to avoid depressive episodes that leave me completely debilitated, unable to get out of bed.

Research, writing, and advocating for Alzheimer’s awareness are my happy activities. Of course, Linda and the cats are the bright spots of my life.

How am I doing in the fight against Alzheimer’s? Better than I expected at this point in time. For the most part, I credit the Lecanemab infusions for slowing down the Alzheimer’s progression and for giving me hope.

$25 Purchase Now

Your support of my blog is greatly needed - and, appreciated.

There are three ways you can support the publication:

• Sometimes: Donate whatever you can, whenever you can. You will continue to have full access to the entire blog - nothing changes for you, and your support is deeply appreciated.

• Supporters (minimum donation of $25/month): You’ll receive full access to the blog, my new Saturday feature, The Week in Review, and a permanent 5% discount at my online store.

• Sponsors (minimum donation of $40/month): You’ll receive all the Supporter benefits plus a permanent 8% store discount and an invitation to a monthly live Zoom meeting. This will be an open space to talk, share, and ask me almost anything on your mind. I will schedule multiple times if needed to make sure our international friends can join in.

I never want a person’s financial situation to stand between them and the support they find here, but I also want to ensure My Alzheimer’s Journey is sustainable. If you’re able to, please consider contributing so I can continue to share insight with you and the many caregivers and families who are following My Alzheimer’s Journey.

Please support at the level that feels right for you. I am so grateful to have you alongside me on my Alzheimer’s journey.

Donations

Why I Ask for Donations

Sponsor Donations

Go Fund Me

Buy Big Bit A Treat

Amazon Wish List

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

On April 30, Axsome Therapeutics’s Auvelity got full approval from the Food and Drug Administration (FDA), becoming the second medication approved for treating agitation related to Alzheimer’s. Unlike the antipsychotic Rexulti (generic name: brexpiprazole), which was approved in 2024 after showing a small benefit on agitation symptoms, it doesn’t seem to increase mortality risk. Rexulti carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis.

Auvelity was approved in August 2022 for treating major depressive disorder (MDD) in adults. Major depressive disorder affects an estimated 280 million people globally and is a leading cause of disability worldwide. Auvelity has shown to start working for some people as early as one week. To date, Auvelity has been administered to more than 300,000 patients.

Auvelity is a combination of two medications, dextromethorphan and bupropion. These two drugs affect brain pathways responsible for mood regulation and stress responses, two networks thought to be involved in the agitation-related behavioral changes associated with Alzheimer’s.

Auvelity is not to be taken on an as needed basis. Dosing will be gradually increased over time depending on the patient tolerability. Patients start with 30 mg/105 mg (dextromethorphan 30 mg/bupropion 105 mg) once daily for 7 days, increase to twice daily on Day 8, and may reach the maximum dose of 45 mg/105 mg twice daily by Day 15.

Many physicians are less than enthusiastic about Auvelity as treatment for agitation related to Alzheimer’s. They have concerns about Axsome’s delayed release of data, and Auvelity’s lack of peer-reviewed studies. Axsome ran four Phase 3 trials to show its efficacy, though the data for most of the trials are not yet published in peer-reviewed scientific journals.

In 2020, the company shared data from the first trial showing a modest reduction in agitation. Some researchers suggest this small change would not be noticeable by patients and caregivers.

In 2022, data from the second Phase 3 trial was released by Axsome. That study involved following people who responded well to the drug, and then for half of the participants, replacing the active treatment with a placebo to see when symptoms return. That study showed people continuing to take the drug were less likely to experience a relapse in symptoms.

These two studies were the basis for FDA approval April 30.

Overall, the effect of Auvelty for treatment of agitation related to Alzheimer’s has been characterized by some physicians as modest. Yet, Auvelty is considered a much safer drug than Ruxelti; thus giving it an advantage. The most common side effects were dizziness, headache, and nausea and the drug didn’t seem to increase the risk of mortality.

So far, none of the agitation drugs on the market show a very large effect on symptoms. Non-pharmaceutical interventions seem to be the best front-line treatment. Caregivers know what works best for their loved one or patient, for example, music, a calm environment, or limited distractions. Auvelty may be worth trying for several months to see if it is effective.

$25 Purchase Now

Your support of my blog is greatly needed - and, appreciated.

There are three ways you can support the publication:

• Sometimes: Donate whatever you can, whenever you can. You will continue to have full access to the entire blog - nothing changes for you, and your support is deeply appreciated.

• Supporters (minimum donation of $25/month): You’ll receive full access to the blog, my new Saturday feature, The Week in Review, and a permanent 5% discount at my online store.

• Sponsors (minimum donation of $40/month): You’ll receive all the Supporter benefits plus a permanent 8% store discount and an invitation to a monthly live Zoom meeting. This will be an open space to talk, share, and ask me almost anything on your mind. I will schedule multiple times if needed to make sure our international friends can join in.

I never want a person’s financial situation to stand between them and the support they find here, but I also want to ensure My Alzheimer’s Journey is sustainable. If you’re able to, please consider contributing so I can continue to share insight with you and the many caregivers and families who are following My Alzheimer’s Journey.

Please support at the level that feels right for you. I am so grateful to have you alongside me on my Alzheimer’s journey.

Donations

Why I Ask for Donations

Sponsor Donations

Go Fund Me

Buy Big Bit A Treat

Amazon Wish List

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

This special article will be emailed to my Supporters (minimum of $25 per month donation). This Saturday and next Saturday I am sending The Week In Review. to everyone.

Monday, I wrote about AbbVie’s amyloid beta antibody known as ABBV-1758. AbbVie acquired this drug when they purchased Aliada in late 2024. While ABBV-1758 is impressive and shows early promise, the bigger story is the delivery technology - MODEL. Breaking the BBB is a goal of every neurological research scientist. I seem to visualize the BBB as a membrane surrounding the brain. According to Tanya Wallace, PhD, vice president of neuroscience discovery research at AbbVie, “despite the BBB’s importance, many seemingly basic biological questions remain unanswered, fueling additional global research.” The BBB consists of both cellular and acellular components. It is a sophisticated structure that regulates information flow between the periphery and the brain. Over the next several weeks, I will write more about the BBB so we can understand that the BBB is much more than just a membrane.

I wrote the Tuesday post while receiving my fifteenth Lecanemab infusion at the Duke Specialty Infusion Center. As I tend to do occasionally, I stepped up on my soapbox and spoke about the need for additional research dollars. I certainly never want to offend anyone while yelling from my soapbox. Yet, many things in Washington do not make sense to me. Can you imagine the impact one billion dollars would have on cancer and Alzheimer’s research?

I also reminded everyone to consider supporting my work with a monthly donation. While some people have sent donations, the vast majority have not. This is a frustrating situation for me. I average three hours per day researching and writing. I subscribe to several scientific journals. Additionally, there are basic office expenses and maintaining hardware and software. Most importantly, Linda and I need a source of income to bridge the gap between our Social Security income and my direct and indirect treatment expenses. If you find my articles have value, please consider supporting me at either the $25 or $40 per month level.

Wednesday, I wrote about the challenge managing agitation behaviors. I devoted most of the article to the new experimental drug, Masupirdine. This drug will soon begin Phase 3 clinical trials. I am excited about the potential of this therapy. What I did not know Wednesday is Axsome Therapeutics new agitation treatment drug, Auvelity would receive FDA approval the next day. It is great that agitation behaviors are getting a lot of attention. I will write about Auvelity Monday.

The Bio-Hermes study was the Thursday topic. Over the next year (and beyond), I believe the results of this project will be expanded by many leading biotechnology companies. The ability of a blood test to identity amyloid plaque and tau tangles has huge potential in terms of early diagnosis of Alzheimer’s.

I wrapped up the week with Fun Friday. The peaceful marches for International Workers’ Day were much larger than I expected. Did anyone really pay attention though? As an optimist and a lover of American democracy, I hope someone understands the current frustration of many people.

While writing this article, Big Bit has been begging for food. Her bowl is full, so I have attempted to ignore her. As this video shows, that is always a challenge.

Thank you for your support. Have a great rest of the weekend.

Only $24.90 - Click and Buy Now

From the moment I began My Alzheimer’s Journey, I knew that I wanted to build a space that was free and accessible to everyone - a resource for the patients, caregivers, researchers, and medical professionals who need this information most.

As this community has grown, so have the costs of keeping it running. Between professional journal subscriptions, scientific research purchases, and the several hours of research and writing I put into every single post, the expenses have become significant. While I’ve received occasional donations in the past, they haven’t been consistent enough to cover these mounting costs.

To ensure this blog remains a high-quality resource for the long haul, I’ve decided to formalize how you can support this mission. There are three ways you can support the publication:

• Sometimes: Donate whatever you can, whenever you can. You will continue to have full access to the entire blog - nothing changes for you, and your support is deeply appreciated.

• Supporters (minimum donation of $25/month): You’ll receive full access to the blog, my new Saturday feature, The Week in Review, and a permanent 5% discount at my online store.

• Sponsors (minimum donation of $40/month): You’ll receive all the Supporter benefits plus a permanent 8% store discount and an invitation to a monthly live Zoom meeting. This will be an open space to talk, share, and ask me almost anything on your mind. I will schedule multiple times if needed to make sure our international friends can join in.

I never want a person’s financial situation to stand between them and the support they find here, but I also want to ensure My Alzheimer’s Journey is sustainable. If you’re able to, please consider contributing so I can continue to share insight with you and the many caregivers and families who are following My Alzheimer’s Journey.

Please support at the level that feels right for you. I am so grateful to have you alongside me on my Alzheimer’s journey.

Donations

Why I Ask for Donations

Sponsor Donations

Go Fund Me

Buy Big Bit A Treat

Amazon Wish List

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

let’s do it today!

There are plenty of music festivals, art shows, and food extravaganzas happening around the world this weekend. May 1 is also an important historical day.

International Worker’s Day began on May 1, 1886, in Chicago. Thousands of workers took to the streets to demand an eight-hour work day. Today, International Workers’ Day commemorates the struggle of workers to overcome labor challenges in both the past and the present.

Speaking of the present, North Carolina teachers walked out and are protesting today. North Carolina ranks 46th in the nation for teacher pay. The teachers are demanding higher pay, increased school funding, and better working conditions. Interestingly, North Carolina has not passed a budget since 2023.

Before we run back the calendar, Axsome Therapeutics announced this morning FDA approval of Auvelity for the treatment of agitation associated with Alzheimer’s disease. Look for a full report Monday.

The first adhesive postage stamp was issued May 1, 1840, in the United Kingdom.

Speaking of the Brits, on May 1, 1927, Imperial Airlines became the first British airliner to serve cooked meals. Good luck even getting a cold meal on a flight today.

Staying with transportation Amtrak began operations May 1, 1971, with its first train running from New York City to Philadelphia.

Sponge Bob SquarePants debut on Nickelodeon May 1, 1999.

Calamity Jane was born May 1, 1852. Do you not know who she is? Calamity Jane was an American frontierswoman. She participated in Buffalo Bill's Wild West show and the 1901 Pan-American Exposition, showcasing her frontier experiences. Jane claimed a close relationship with Wild Bill Hickok, though that has been disputed by history buffs. What hasn’t been disputed is her fondness for wearing men’s clothing and drinking heavily.

Need weekend plans?

My top five suggestions are:

1. Beachlife Festival 2026 (Redondo Beach, CA) James Taylor is one of the many performers!

2. Army vs. Navy Rugby Match (Allianz Stadium, London) The stadium is only six miles from Heathrow Airport.

3. Aotcaroa Art Festival (Auckland) This is so much more than just an art festival!

4. Pirates & Wenches Weekend (Seymour, IN) Don’t miss the formal Pirates Ball Saturday evening.

5. Faerie Fest: The Flower Moon (Duncansville, PA) “magical two days”

I think that is enough fun for this Friday.

I hope you have a great weekend, no matter what you do or don’t do. The cats and I are counting the hours until Linda comes home Sunday.

Not to be a pest, but please make a decision about your level of support for this blog. If I don’t receive monetary support for my work, I may have to find a job as a waiter at Succotash Southern and Creole Kitchen in Durham. With my failing memory, someone would get Fried Green Tomatoes when they ordered Roasted Broccoli. I think I should stick to research and writing.

Only $24.90 - Click and Buy Now

From the moment I began My Alzheimer’s Journey, I knew that I wanted to build a space that was free and accessible to everyone - a resource for the patients, caregivers, researchers, and medical professionals who need this information most.

As this community has grown, so have the costs of keeping it running. Between professional journal subscriptions, scientific research purchases, and the several hours of research and writing I put into every single post, the expenses have become significant. While I’ve received occasional donations in the past, they haven’t been consistent enough to cover these mounting costs.

To ensure this blog remains a high-quality resource for the long haul, I’ve decided to formalize how you can support this mission. There are three ways you can support the publication:

• Sometimes: Donate whatever you can, whenever you can. You will continue to have full access to the entire blog - nothing changes for you, and your support is deeply appreciated.

• Supporters (minimum donation of $25/month): You’ll receive full access to the blog, my new Saturday feature, The Week in Review, and a permanent 5% discount at my online store.

• Sponsors (minimum donation of $40/month): You’ll receive all the Supporter benefits plus a permanent 8% store discount and an invitation to a monthly live Zoom meeting. This will be an open space to talk, share, and ask me almost anything on your mind. I will schedule multiple times if needed to make sure our international friends can join in.

I never want a person’s financial situation to stand between them and the support they find here, but I also want to ensure My Alzheimer’s Journey is sustainable. If you’re able to, please consider contributing so I can continue to share insight with you and the many caregivers and families who are following My Alzheimer’s Journey.

Please support at the level that feels right for you. I am so grateful to have you alongside me on my Alzheimer’s journey.

Donations

Why I Ask for Donations

Sponsor Donations

Go Fund Me

Buy Big Bit A Treat

Amazon Wish List

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts

I published an article January 26 about a study (Bio-Hermes) to determine if blood and digital biomarkers can reflect the presence of brain amyloid plaques. Today, I have an update on the study.

The Global Alzheimer’s Platform (GAP) recently announced the Bio-Hermes study has been successfully completed. What exactly does successfully completed mean?

The Bio-Hermes study had more than 1000 participants. The participants represented a diverse population, both ethnically and by health status:

• 24% percent of the participants were from traditionally underrepresented communities

• 400+ participants were considered healthy because they did not report any memory or thinking problems

• 300+ participants had MCI (Mild Cognitive Impairment)

• 270+ participants had early stage Alzheimer’s disease

The participants were given two blood and digital biomarker tests and one PET (Positron Emission Tomography) scan. The blood tests included the PrecivityAD test and the p-Tau217 test. Both tests are proven to be highly accurate in detecting Alzheimer’s disease pathology. The PrecivityAD test identifies amyloid plaques and the p-Tau217 test will identify both amyloid plaques and tau tangles.

The blood tests showed an Overall Percent Agreement (the proportion of total study participants where two or more tests agree) of 80.7% and a Positive Predictive Value (the probability that subjects with a positive screening test truly have the disease) of 90.1%.

In other words, the blood and digital biomarker tests accurately matched the PET scan results at a very high percentage of accuracy.

In case you have questions about the accuracy of the Bio-Hermes study, the researchers included 25 blood-based biomarkers, 15 digital tests (speech analytics, computerized cognitive assessment using adaptive psychophysics, and digital remote brain health screenings), and 4 cognitive tests (retinal imaging, PET Central Reader, statistical analysis, and artificial intelligence).

The positive results of the Bio-Hermes study is a significant step forward for early Alzheimer’s disease screening and for researchers.

Siemens Healthineers has joined the Bio-Hermes program to take its capabilities to the next level. Siemens is now a licensed partner of the study, aiming to enhance Alzheimer’s diagnostics. Several other leading biotech and pharmaceutical companies are also joining the Bio-Hermes program. The names of the other companies have not been announced.

These companies and universities participated in and supported the initial Bio-Hermes study:

• AbbVie

• Alzheimer’s Drug Discovery Foundation (ADDF)

• Aural Analytics

• C2N

• Cognivue

• EMTherapro

• Gates Ventures

• GNS Healthcare

• IXICO

• Lilly

• Linus

• Merck

• Pentara

• Quanterix

• Retispec

• Roche

• SomaLogic

• University of Gothenburg

My guess is that you will see many of the above organizations becoming official partners of the study.

I will continue to follow the Bio-Hermes program.

SOURCE: Interchangeability of blood-based biomarkers and PET to identify Alzheimer’s disease pathology

Only $24.90 - Click and Buy Now

From the moment I began My Alzheimer’s Journey, I knew that I wanted to build a space that was free and accessible to everyone - a resource for the patients, caregivers, researchers, and medical professionals who need this information most.

As this community has grown, so have the costs of keeping it running. Between professional journal subscriptions, scientific research purchases, and the several hours of research and writing I put into every single post, the expenses have become significant. While I’ve received occasional donations in the past, they haven’t been consistent enough to cover these mounting costs.

To ensure this blog remains a high-quality resource for the long haul, I’ve decided to formalize how you can support this mission. There are three ways you can support the publication:

• Sometimes: Donate whatever you can, whenever you can. You will continue to have full access to the entire blog - nothing changes for you, and your support is deeply appreciated.

• Supporters (minimum donation of $25/month): You’ll receive full access to the blog, my new Saturday feature, The Week in Review, and a permanent 5% discount at my online store.

• Sponsors (minimum donation of $40/month): You’ll receive all the Supporter benefits plus a permanent 8% store discount and an invitation to a monthly live Zoom meeting. This will be an open space to talk, share, and ask me almost anything on your mind. I will schedule multiple times if needed to make sure our international friends can join in.

I never want a person’s financial situation to stand between them and the support they find here, but I also want to ensure My Alzheimer’s Journey is sustainable. If you’re able to, please consider contributing so I can continue to share insight with you and the many caregivers and families who are following My Alzheimer’s Journey.

Please support at the level that feels right for you. I am so grateful to have you alongside me on my Alzheimer’s journey.

Donations

Why I Ask for Donations

Sponsor Donations

Go Fund Me

Buy Big Bit A Treat

Amazon Wish List

Shopping

Greg’s AZ Store

About

Greg’s Story

Interested In Greg Speaking At Your Event?

More Information

Search

Search All Posts